Treating depression with ketamine: We need incremental treatment for depression
Recently, the Food and Drug Administration approved a nasal spray version of the drug Ketamine, named Spravato (esketamine), for use as a supplement to oral antidepressants taken by adults living with treatment-resistant depression.
The announcement was accompanied by a flurry of media excitement as Spravato is the first medication for depression with a new mechanism of action since Prozac (fluoxetine hydrochloride) was approved in the late 1980s.
The risks …
Treating depression with ketamine: We need incremental treatment for depression


![Clinicians are failing at value-based care because no one taught them the system [PODCAST]](https://kevinmd.com/wp-content/uploads/bd31ce43-6fb7-4665-a30e-ee0a6b592f4c-190x100.jpeg)












![Why cervical cancer screening drops after menopause, and why that’s dangerous [PODCAST]](https://kevinmd.com/wp-content/uploads/Gemini_Generated_Image_h8guhqh8guhqh8gu-190x100.png)